Clinical trials
Completed Phase 2 Multiple Sclerosis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
143 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 4 |
| 2002 | 5 |
| 2003 | 7 |
| 2004 | 5 |
| 2005 | 9 |
| 2006 | 11 |
| 2007 | 6 |
| 2008 | 7 |
| 2009 | 9 |
| 2010 | 11 |
| 2011 | 9 |
| 2012 | 8 |
| 2013 | 4 |
| 2014 | 7 |
| 2015 | 8 |
| 2016 | 4 |
| 2017 | 1 |
| 2018 | 6 |
| 2019 | 5 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 143 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Biogen | 12 |
| Sanofi | 8 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 7 |
| GlaxoSmithKline | 5 |
| Merck KGaA, Darmstadt, Germany | 4 |
| Novartis | 4 |
| Novartis Pharmaceuticals | 4 |
| Rigshospitalet, Denmark | 3 |
| University College, London | 3 |
| VA Office of Research and Development | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Sclerosis | 143 |
| Multiple Sclerosis, Relapsing-Remitting | 31 |
| Multiple Sclerosis, Chronic Progressive | 11 |
| Fatigue | 7 |
| Recurrence | 7 |
| Demyelinating Diseases | 4 |
| Muscle Spasticity | 4 |
| Optic Neuritis | 4 |
| Autoimmune Diseases | 3 |
| Inflammation | 2 |
Trials
Showing 1 to 25 of 143. Each trial links to its page on Pharma Observatory.
43 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.